Shore Capital view: Creo Medical (‘CREO’) is at a commercial inflection point. In FY25, sales of its surgical endoscopy tools grew substantially (+50%) despite a tightening cost base (-20%), establishing that
Shore Capital view: Creo Medical (‘CREO’) is at a commercial inflection point. In FY25, sales of its surgical endoscopy tools grew substantially (+50%) despite a tightening cost base (-20%), establishing that
Its been another busy week for London’s junior mining sector, here we take a look at the movers and shakers
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.